BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 14, 2025
See today's BioWorld
Home
» Awake to Vigil’s TREM2 strategy, backers assemble $90M series B
To read the full story,
subscribe
or
sign in
.
Awake to Vigil’s TREM2 strategy, backers assemble $90M series B
Aug. 18, 2021
By
Randy Osborne
Vigil Neuroscience Inc. CEO Ivana Magovčević-Liebisch said the just-raised $90 million in series B money will let the company reach “a lot of value-generating milestones,” having been “moving extremely fast” in the year since it was founded.
BioWorld
Financings
Neurology/psychiatric
Series B